Treatment with nomacopan in six patients in Phase II trial was well tolerated and resulted in rapid onset of clinical improvement in five of six patientsNo …
Akari Therapeutics to Participate in Ladenburg Thalmann Healthcare Conference
NEW YORK and LONDON, September 18, 2019 – Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan …
[Read more...] about Akari Therapeutics to Participate in Ladenburg Thalmann Healthcare Conference
Akari Therapeutics’ Nomacopan Granted U.S. Orphan Drug Designation for Bullous Pemphigoid
NEW YORK and LONDON, September 13, 2019 – Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan …
Akari Therapeutics to Participate in Citi and H.C. Wainwright Conferences in Early September
NEW YORK and LONDON, September 3, 2019 – Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan …
Akari Therapeutics’ Nomacopan Granted U.S. Orphan Drug Designation for Hematopoietic Stem Cell Transplantation-Associated Thrombotic Microangiopathy (HSCT-TMA)
NEW YORK and LONDON, August 30, 2019 – Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan …
